Swedish Orphan Biovitrum AB

Type: Company
Name: Swedish Orphan Biovitrum AB (Biovitrum AB)
Nationality: Sweden
Web Address: http://www.biovitrum.com/
Fact Sheet: Fact Sheet for Biovitrum AB
First reported 17 mins ago - Updated 8 mins ago - 1 reports

Insights & Highlights from the Dohmen Life Science Services 2014 Entrepreneur Summit

Dohmen Life Science Services held their first Entrepreneur Summit, lastweek at the Harley Davidson Museum in Milwaukee, drawing more than 100executives to reimagine the future of the life sciences industry.Panels Share Key Insights: Life Science entrepreneurs ... [Published 4 Traders - 17 mins ago]
First reported Oct 30 2014 - Updated 23 hours ago - 1 reports

Pharming : Reports On Financial Results For The First Nine Months Of 2014

Pharming Reports On Financial Results For The First Nine Months Of 2014Leiden, The Netherlands, 30 October 2014.  Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today published its financial report for the nine ... [Published 4 Traders - Oct 30 2014]
First reported Oct 30 2014 - Updated Oct 30 2014 - 2 reports

SOBI increases revenues by 25%, boosted by a doubling of Orfadin sales

Biotech firm Swedish Orphan Biovitrum (SOBI: SS), has announced total revenues of 665.9 million Swedish kronor ($99.8 million) for the third quarter of 2014, an increase of 25.2% on figures from the same period last year.Orfadin doubles its salesProduct ... [Published Pharma Letter - Oct 30 2014]
First reported Oct 30 2014 - Updated Oct 30 2014 - 1 reports

Sobi publishes Report for the Third Quarter 2014

Swedish Orphan Biovitrum AB (publ) (Sobi) announced today its results for the third quarter 2014. Revenue totalled SEK 666 M (517), an increase of 29 per cent with contribution from all areas of the portfolio. Product revenues excluding income from Manufacturing ... [Published Nasdaq - Oct 30 2014]
First reported Oct 30 2014 - Updated Oct 30 2014 - 1 reports

BRIEF-SOBI posts sharply higher Q3 EBITA, repeats full-year outlook

STOCKHOLM Oct 30 (Reuters) - Swedish Orphan Biovitrum PublAb* Q3 sales 665.9 million SEK versus mean forecast 615million sek* Q3 gross margin was 59 percent* Says outlook 2014 unchanged* Q3 EBITA was SEK 119.9 m (46.9), mean forecast was for68.2 mln in ... [Published Reuters UK - Oct 30 2014]
First reported Oct 23 2014 - Updated Oct 23 2014 - 1 reports

Hanover appoints new European head of healthcare

:13 in Marketing Services Hanover has announced the return of Emma Eatwell to the agency, taking over the role of European healthcare head. Ms Eatwell originally Hanover last year to become head of public policy and advocacy at Swedish Orphan Biovitrum, ... [Published Zenopa - Oct 23 2014]
First reported Oct 21 2014 - Updated Oct 21 2014 - 1 reports

Emma Eatwell returns to Hanover

Hanover reappoints Emma Eatwell to head its Brussels Healthcare Business.She will advise Hanover’s healthcare clients on corporate and brand agendas in Brussels, and on market and patient access campaigns across Europe.Emma left the company in April 2013, ... [Published GorkanaPR - Oct 21 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Invitation - Presentation of Sobi's third quarter results 2014

Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the third quarter 2014. Financial analysts and media are invited to participate in a telephone conference, which will ... ... [Published Yahoo! Finance UK and Ireland - Oct 16 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Invitation - Presentation of Sobi''s third quarter results 2014

Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the third quarter 2014.Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, at 13:00 CET (08:00 EST). ... [Published Nasdaq - Oct 16 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 2 reports

Pharming and Swedish Orphan Biovitrum amends and extends Ruconest distribution agreement in Austria, Germany and Netherlands

Biotech company Pharming Group NV (Amsterdam:PHARM.AS) reported on Monday the amendment and extension of the Ruconest distribution agreement with Swedish Orphan Biovitrum AB (publ) (SS:SOBI).With immediate effect, Pharming will focus on Ruconest's direct ... [Published Individual.com - Oct 14 2014]
First reported Oct 13 2014 - Updated Oct 13 2014 - 5 reports

Pharming and Sobi amend and extend Ruconest distribution agreement

Pharming Group NV and Swedish Orphan Biovitrum AB, or Sobi, has announced the amendment and extension of the Ruconest distribution agreement between Pharming and Sobi. Effective immediately, Pharming will focus on direct commercialization in Austria, ... [Published Individual.com - Oct 13 2014]
First reported Oct 09 2014 - Updated Oct 09 2014 - 2 reports

Sobi's collaboration partner Biogen Idec files marketing authorisation application for Elocta(TM) (rFVIIIFc) in Europe

, Sobi had total revenues of SEK 2.2 billion (€253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.For more information please contact:Media relations Investor relatio ... [Published ACN Newswire - Oct 09 2014]

Quotes

Geoffrey McDonough, chief executive and president, said: "The third quarter results come at an exciting time for SOBI, marked by excellent operating momentum and by a key transition in our pipeline as the launches of Eloctate (antihemophilic factor) and Alprolix (coagulation factor) continue. Elocta, as Eloctate will be known in Europe, is potentially entering its approval year following the submission of the Marketing Authorization Application (MAA) to the European Medicines Agency by our partner Biogen Idec.”"
Geoffrey McDonough, CEO and President, said in a statement, "The third quarter results come at an exciting time for Sobi, marked by excellent operating momentum across the portfolio, and by a key transition in our pipeline as the launches of Eloctate(TM) and Alprolix® continue."
...and by a key transition in our pipeline as the launches of Eloctate(TM) and Alprolix® continue", said Geoffrey McDonough, CEO and President. "Elocta, as Eloctate will be known in Europe, now enters its potential approval year following the submission of the Marketing Authorization Application to the European Medicines Agency by our partner Biogen Idec. We are focusing the company on bringing this new generation of therapy to people with Haemophilia across Europe."
Sijmen de Vries, Chief Executive Officer of Pharming, commented: "During this first nine months of 2014 we prepared for US market entry by investing in building inventories of Ruconest®.  At the same time, we strengthen the balance sheet with a  "sub-10%" private placement to institutional investors that yielded €14.7 million, which ensured that we were able to co- invest to develop our main asset Ruconest®  for additional indications, such as the start of the Phase II clinical study in prophylaxis of HAE InIn addition, we announced our involvement in direct commercialization activities in Austria, Germany and Netherlands."

More Content

All (65) | News (41) | Reports (0) | Blogs (8) | Audio/Video (0) | Fact Sheets (2) | Press Releases (14)
sort by: Date | Relevance
Insights & Highlights from the Dohmen Life Scie... [Published 4 Traders - 17 mins ago]
Weekly prophylaxis with nonacog beta pegol safe... [Published Orthopedics Today - 7 hours ago]
Pharming Reports On Financial Results For The F... [Published BioSpace - 23 hours ago]
SOBI increases revenues by 25%, boosted by a do... [Published Pharma Letter - Oct 30 2014]
Swedish Orphan Biovitrum Posts 3Q Profit, Reven... [Published RTTNews.com - Oct 30 2014]
BRIEF-SOBI posts sharply higher Q3 EBITA, repea... [Published Reuters UK - Oct 30 2014]
Sobi publishes Report for the Third Quarter 2014 [Published Nasdaq - Oct 30 2014]
Pharming : Reports On Financial Results For The... [Published 4 Traders - Oct 30 2014]
Biogen Decline Over PML Tied To Tecfidera, Offe... [Published Seeking Alpha - Oct 28 2014]
Hanover appoints new European head of healthcare [Published Zenopa - Oct 23 2014]
Emma Eatwell returns to Hanover [Published PMLive - Oct 23 2014]
Emma Eatwell returns to Hanover [Published GorkanaPR - Oct 21 2014]
BioSpecifics Technologies Corp. Announces FDA A... [Published Myrtle Beach Sun News - Oct 21 2014]
BioSpecifics Technologies Corp. Announces Prese... [Published Fat Pitch Financials - Oct 16 2014]
BioSpecifics Technologies Corp. Announces Prese... [Published Stock Nod - Oct 16 2014]
Invitation - Presentation of Sobi's third quart... [Published Yahoo! Finance UK and Ireland - Oct 16 2014]
Invitation - Presentation of Sobi''s third quar... [Published Nasdaq - Oct 16 2014]
Biotech bucks macro uncertainties - strong quar... [Published Nasdaq - Oct 16 2014]
Pharming and Swedish Orphan Biovitrum amends an... [Published Individual.com - Oct 14 2014]
PHARMING : PHARM: Optimizing Ruconest Distribut... [Published 4 Traders - Oct 14 2014]
Pharming and Sobi amend and extend Ruconest dis... [Published Individual.com - Oct 13 2014]
SOBI and Pharming extend and amend Ruconest agr... [Published Pharma Letter - Oct 13 2014]
BRIEF-Pharming and SOBI extend distribution agr... [Published Reuters - Oct 13 2014]
Pharming and Swedish Orphan Biovitrum Amend and... [Published ADVFN UK - Oct 13 2014]
Pharming and Swedish Orphan Biovitrum Amend and... [Published 4 Traders - Oct 13 2014]
Sobi's collaboration partner Biogen Idec files ... [Published ACN Newswire - Oct 09 2014]
Sobi’s collaboration partner Biogen Idec files ... [Published MyNewsDesk - Oct 09 2014]
BioSpecifics Technologies Corp. Announces Sudde... [Published Town Hall - Oct 08 2014]
Sobi opens North American operations [Published ACN Newswire - Sep 22 2014]
Biogen Idec Offers Growth Investors An Attracti... [Published BioPortfolio - Sep 22 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Sobi seeks EMA approval for Xiapex for Peyronie... [Published PBR - News - Jun 26 2014]
Swedish Orphan Biovitrum (Sobi) has filed for an extension of the label for Xiapex with the European Medicines Agency (EMA) to include the indication of Peyronie's disease. ...
BioSpecifics Technologies Corp. Announces Filin... [Published PR Newswire: Health - Jun 25 2014]
LYNBROOK, N.Y., June 25, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, announced today that ...
Sobi files for EU approval of Xiapex for Peyron... [Published PR Newswire: Financial Services - Jun 25 2014]
STOCKHOLM and CHESTERBROOK, Pa., June 25, 2014 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. today announced that Sobi has filed for an extension of the label for Xiapex® (collagenase clostridium histolyticum) ...
ORFADIN (Nitisinone) Capsule [SWEDISH ORPHAN BI... [Published DailyMed Drug Label Updates for the last seven ... - Jun 15 2014]
Updated Date: Jun 11, 2014 EST ...
Biogen, Sobi pledge hemophilia drug donation in... [Published Yahoo! Health News - May 12 2014]
Biogen Idec Inc and partner Swedish Orphan Biovitrum AB on Monday said they will donate hemophilia drugs for use in developing nations in quantities large enough to treat tens of thousands of patients over the next decade. The potentially life-sa... ...
1 2

Press Releases

sort by: Date | Relevance
Sobi expands Haemophilia development portfolio ... [Published GlobeNewswire: Acquisitions News - Sep 19 2014]
New number of shares and votes in Swedish Orpha... [Published GlobeNewswire: Advertising News - Jul 31 2014]
Sobi's board of directors exercises authorisati... [Published GlobeNewswire: Acquisitions News - Jul 18 2014]
Sobi awarded Company of the Year at the Europea... [Published GlobeNewswire: Acquisitions News - Jul 01 2014]
Sobi files for EU approval of Xiapex for Peyron... [Published GlobeNewswire: Advertising News - Jun 25 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.